Comment

  • 29 March 2017

    FDA raises warning flag over Viberzi safety in IBS-D

    In March 2017, the FDA issued a warning against Allergan’s Viberzi (eluxadoline), which was approved in May 2015 in the US for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D).

Close
Close
Close

Go Top